Braveheart Bio
PVT · PVT·San Francisco, CA·Private·Phase 2
Launched in November 2025 with $185M Series A led by a16z Bio+Health, Forbion, OrbiMed, Enavate Sciences, and Frazier Life Sciences. Developing BHB-1893, a next-generation selective cardiac myosin inhibitor licensed from Hengrui Pharma, for hypertrophic cardiomyopathy. Positive Phase 2 data in oHCM showed rapid LVOT gradient reduction with minimal LVEF impact and no dose-limiting titration. Led by CEO Travis Murdoch (former HI-Bio CEO); chaired by Biogen CEO Chris Viehbacher.
Decks (1)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| Braveheart Bio website | Website | May 6, 2026 | 3 |